NEUROREGEN™: Advancing Neuroregeneration for Parkinson’s and Beyond
NEUROREGEN™ is our next-generation multimodal therapeutic platform designed to stimulate myelin repair, axonal regeneration, and neuroplasticity. Our proprietary approach integrates small molecule modulation, targeted receptor activation, and neurotrophic enhancement—offering new hope for neurodegenerative conditions like Parkinson’s Disease, Multiple Sclerosis, and CNS injury.
Built upon a foundation of extensive molecular docking, dynamics simulation, and preclinical strategy, NEUROREGEN™ targets key nodes such as PDE4, CB2, BDNF, and Nogo-A, orchestrating a coordinated neurorestorative response. This data-driven design ensures both mechanistic specificity and translational potential.
We are actively progressing toward in vivo validation, partnering with leading research institutions and exploring grant-backed support through organizations like the Shake It Up Australia Foundation and Michael J. Fox Foundation.
Key Highlights:
Key Highlights:– Multi-targeted approach: Combining remyelination, axonal regeneration, and synaptic recovery
– AI-optimized molecular analogs: Structurally enhanced to maximize receptor binding and pharmacokinetics
– Validated through simulation: 50–100 ns MD simulations, MM/PBSA energy analysis, and hydration mapping
– Preclinical pipeline active: Ethical animal models selected; ADMET and toxicity studies in preparation
If you are a research collaborator, CRO, or funding partner interested in accelerating clinical translation, we invite you to connect with our team.
NEUROREGEN™ is more than a product. It’s a platform for regeneration—engineered at the molecular level, driven by purpose.